Abstract: A cellular model is described that targets dysregulation or inappropriate activation of the Sonic Hedgehog/Patched (SHH/PTCH) pathway. Also described is a screening method using this cellular model to screen for pharmacological compounds that can treat or prevent skin cancer, in particular, Basal Cell Carcinoma (BCC) lesions.

Abstract: A method of characterizing specific microbiota associated with Demodex mites from a rosacea patient is described. The method can include a step of realizing a biopsy on the patient and analyzing the microbiota based on a method of 16SrRNA sequencing or pyrosequencing. A method for the diagnosis of rosacea in a patient is also described. This method can include characterizing microbiota associated with Demodex mites in the patient. Also described, are methods of differentiating a subtype of rosacea in a patient with rosacea and methods of controlling and measuring an active agent's treatment effectiveness on rosacea.

Abstract: Described herein is a method of using a topical, pharmaceutical composition, particularly a dermatological composition, comprising naratriptan to treat rosacea and in particular erythematotelangiectatic rosacea.

Abstract: A cellular model is described that targets dysregulation or inappropriate activation of the Sonic Hedgehog/Patched (SHH/PTCH) pathway. Also described, is a screening method using this cellular model to screen for pharmacological compounds that can treat or prevent skin cancer, in particular, Basal Cell Carcinoma (BCC) lesions.

Abstract: A method of characterizing specific microbiota associated with Demodex mites from a rosacea patient is described. The method can include a step of realizing a biopsy on the patient and analyzing the microbiota based on a method of 16SrRNA sequencing or pyrosequencing. A method for the diagnosis of rosacea in a patient is also described. This method can include characterizing microbiota associated with Demodex mites in the patient. Also described, are methods of differentiating a subtype of rosacea in a patient with rosacea and methods of controlling and measuring an active agent's treatment effectiveness on rosacea.

Abstract: A cellular model is described that targets dysregulation or inappropriate activation of the Sonic Hedgehog/Patched (SHH/PTCH) pathway. Also described, is a screening method using this cellular model to screen for pharmacological compounds that can treat or prevent skin cancer, in particular, Basal Cell Carcinoma (BCC) lesions.

Abstract: An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRP) cation channel, subfamily A, member 1(TRPA1), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology.

Abstract: A compound of formula (I): or a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, or hydrate thereof are described. Also described, is the use of such a compound, salt, solvate or hydrate in the preparation of a medicament intended to treat rosacea.

Abstract: Markers for rosacea among the chemokines and cytokines and their receptors, selected from interleukin 8 (IL-8), CXCL1, CXCL2, CXCL3 and CXCL5, the CXCR1 receptor and the CXCR2 receptor are described. Also described, is a method for the diagnosis of rosacea.

Abstract: The use of compounds in the treatment of skin disorders is described. In particular, the use of a compound of formula (I) or one of its pharmaceutically acceptable salts, pharmaceutically acceptable solvates or hydrates in the preparation of a medicament to treat inflammatory skin pathologies is described.

Abstract: A corrective method is described for processing results of transcriptome experiments obtained by differential analysis includes the following steps: obtaining the results of the level of expression of genes under a reference condition, and calculating the mean level of expression of each of such genes; obtaining the results of the level of expression of such genes under a treatment condition, and calculating the mean level of expression for each of such genes; calculating the modulation coefficient for the level of expression for each of such genes; calculating a p-value associated with each modulation coefficient; and calculating isobar curves of p-value as a function of the mean level of expression of each of such genes under the reference condition; calculating and associating a median modulation coefficient on the isobar curve of each p-value observed. The processing of results of experiments carried out on DNA chips is also described.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the phosphatidylcholine transfer protein (PCTP), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of G0/G1 switch protein 2 (GOS2), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of isovaleryl-coenzyme A dehydrogenase (IVD), and also utilizes modulators of the expression or of the activity of this enzyme, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.

Abstract: Novel N-phenylacetamide compounds of formula (I): and cosmetic and pharmaceutical compositions containing same are useful for treating disorders of the sebaceous gland, e.g., acne, or have cosmetic applications.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the adipose differentiation-related protein (ADFP), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the CYP2B15 and/or glycerol-3-phosphate dehydrogenase 1 (GPD1) proteins.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the CIDEA protein, and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.

Abstract: An in vitro method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of acetyl-coenzyme A acyltransferase 1 (ACAA1) or of acetyl-coenzyme A acyltransferase 2 (ACAA2), and also utilizes modulators of the expression or of the activity of either of these enzymes, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.

Abstract: Novel N-phenylacetamide compounds of formula (I): and cosmetic and pharmaceutical compositions containing same are useful for treating disorders of the sebaceous gland, e.g., acne, or have cosmetic applications.